Navigation Links
Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
Date:4/27/2009

Trial Will Build on Pivotal Phase III Study for the Treatment of Advanced Prostate Cancer

PARSIPPANY, N.J., April 27 /PRNewswire/ -- Ferring Pharmaceuticals announced today the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer. The announcement was made at the 2009 American Urological Association Annual Meeting in Chicago, IL.

The Phase IIIB trial will investigate the use of degarelix for intermittent androgen deprivation therapy (IADT) in patients with advanced prostate cancer who have rising serum PSA levels after previous curative therapies. The study will compare IADT to continuous androgen deprivation therapy (ADT) for 14 months with either leuprolide or degarelix. The trial evaluates whether IADT minimizes the negative effects of ADT and maximizes quality of life, while maintaining tumor response as measured by PSA suppression.

"Intermittent androgen deprivation therapy is a commonly employed treatment for men with biochemical failure, however it needs to be evaluated in a randomized clinical trial," says Dr. E. David Crawford, Head Urologic Oncology, University of Colorado, Denver and a trial investigator. "There is potential value in combining the rapid, sustained suppression of testosterone that degarelix offers in this treatment. IADT appears to improve patient quality of life and that will also be evaluated."

Physicians interested in serving as trial investigators should call 1-973-796-1600 to speak with Ferring Pharmaceuticals' Medical Information office.

Degarelix Phase III Trials

Phase III pivotal studies showed that degarelix is as effective as leuprolide (Lupron Depot(R))(*)in reducing and sustaining castrate levels
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... DUBLIN , July 30, 2014 ... the "Global and Chinese Aseptic Packaging Industry Report ... http://photos.prnewswire.com/prnh/20130307/600769 The Global and ... in-depth study on the current state of the global ... situation. The report provides a basic overview of ...
(Date:7/30/2014)... --  Unique Pizza and Subs Corporation ("Unique," ... Delaware Corporation, is pleased to announce it has ... ("Larasan"), a nature-based pharmaceutical company that produces and distributes ... will work with Unique to help distribute its ... distribution network throughout China ...
(Date:7/30/2014)... and PARIS , July 30, ... ) and Sanofi (EURONEXT: SAN and NYSE: ... ODYSSEY trials of alirocumab in people with hypercholesterolemia met ... from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 ... an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin ...
Breaking Medicine Technology:Global and Chinese Aseptic Packaging Industry Report 2014 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... , , BIRMINGHAM, Ala., Nov. 19 ... the pricing of a public offering of 5,000,000 shares of ... proceeds of $48.75 million. All of the shares are ... statement previously filed with the Securities and Exchange Commission. ...
... TAINAN, Taiwan, Nov. 19 /PRNewswire-Asia/ ... ingredients (APIs), announced that its,Tainan facility has received ... The Certification confirms ScinoPharm,s,competency and proficiency in the ... applies to specific laboratories and,production areas used for ...
Cached Medicine Technology:BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2
(Date:7/31/2014)... people are unaware of getting old. However, the truth is ... we were born on earth. Human beings will experience a ... people may live without children in their old age. In ... to worry about that. A lot of reliable enterprises are ... manufacturer , is one of them. The company is not ...
(Date:7/31/2014)... Care Communications, Inc., (CARE) a national health ... the Elite Award for “Recruitment, Selection and Orientation” from ... elite awards presented as part of “Chicago’s ... 2014 awards competition. This marks the seventh consecutive year ... competition. CARE has also been chosen as a national ...
(Date:7/31/2014)... Recently, iFitDress.com, a professional company of women’s ... by announcing a new collection of high low ... at very low prices. In addition, worldwide clients can ... officials want to save both time and money for ... shopping experience to all online visitors. On its website, ...
(Date:7/31/2014)... National non-profit World T.E.A.M. Sports’ annual ... Range September 12-14, following two years in the high ... of disabled and able-bodied athletes competing together in an ... challenging by experienced adventure athletes. , Hosted at the ... the Colorado River in the rugged Gore Mountains northwest ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 USHIO ... the specialty and general lighting marketplaces, today announced ... kits. These will allow users to transform existing, ... fixtures within minutes. , USHIO America’s Uphoria LED ... 6-inch downlight cans, allowing the user to upgrade ...
Breaking Medicine News(10 mins):Health News:FodayAuto.com: Do Not Be Afraid of Getting Old 2Health News:Care Communications, Inc. Named an Elite Award Winner Among Top Chicago Employers 2Health News:Discounted High Low Wedding Dresses Available At iFitDress.com 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 3Health News:USHIO America Introduces Uphoria™ LED Downlight Retrofit Kits 2
... well known, but a new study has found that it's ... they're given a rewarding task that tests their powers of ... and student colleague Michelle Corman studied men who were each ... raise their blood alcohol level to 0.1, slightly over the ...
... found a gene variant that raises a childs risk ... condition attributed to inflammation of the gastrointestinal tract . ... of a German study that identified the same gene ... disease is a chronic and painful condition attributed to ...
... Scientists have identified the first gene that is linked ... sleep disorder that affects millions of people worldwide . ... overpowering need to move the legs and is also ... ,,We now have concrete evidence that RLS is an ...
... for a swim only to be struck by flesh-eating ... in danger of losing a life, possibly even his ... a tissue-destroying disease caused by a bacterium called Vibrio ... suffering from multiple organ failure because the disease has ...
... revealed that the star had a miscarriage in 2005 . ... ever since they tied the knot in September 2005, and now ... star did in fact become pregnant, but she lost the baby. ... kids of her own. Demi and Ashton have been trying (to ...
... release of more than a thousand prisoners has failed ... and prisoner rehabilitation programmes, said the BMA today. ... anniversary of the Ministry of Justices introduction of emergency ... and Welsh prisons. A key element of the Government ...
Cached Medicine News:Health News:Alcohol may Help You to Be Cool 2Health News:Gene Variants for Crohn's Disease Identified 2Health News:Gene Variants for Crohn's Disease Identified 3Health News:Gene Linked With Restless Leg Syndrome Spotted Out 2Health News:Texan Battles Flesh-eating Bacteria Contracted While Swimming 2Health News:Prison Healthcare Continues to Fail Despite Emergency Measures, Warns BMA 2
... QuickThaw Plasma Thawing Systems from Helmer use both ... times while ensuring the safety of your plasma. ... models have dual baskets with independent controls that ... ,The QuickThaw is also convenient to operate, allowing ...
... systems are automated, easy to operate and ... outside environment by flexible snap-seal pockets which ... viral contamination of the water. Offered in ... can also accommodate bags of various sizes. ...
... Thawing Systems from Helmer use both controlled temperature ... ensuring the safety of your plasma. The DH4 ... dual baskets with independent controls that will accommodate ... is also convenient to operate, allowing you to ...
Inquire...
Medicine Products: